Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections

BMC Infectious Diseases

Table 3 Effect of polymyxin B in different duration, dose and medication mod on curative effect

Group	n	Effective rate (n (%))	Clearance rate (n (%))
Duration of treatment ( days)
3–7	71	16 (16.8%)	12 (16.9%)
8–14	57	35 (61.4%)^a	32 (56.1%)^a
> 14	53	39 (73.5%)^a	32 (60.4%)^a
Daily dose (mg/kg/day)
1.5	70	19 (27.1%)	25 (35.7%)
2.0	97	46 (47.4%)^b	53 (54.6%)^b
2.5	14	10 (71.4%)^b	11 (78.6%)^b
Medication mode
Polymyxin B monotherapy	14	3 (28.57%)	2 (14.29%)
Polymyxin B combination	167	87 (52.1%)^c	74 (44.3%)^c
Carbapenems	39	20 (51.3%)	15 (38.5%)^d
Tigecycline	61	15 (48.4%)	12 (38.7%)^d
Fosfomycin	18	10 (55.6%)	9 (50.0%)^d
Tigecycline + fosfomycin	30	19 (63.3%)	20 (66.7%)
Carbapenems + tigecycline	17	10 (58.8%)	8 (52.9%)^d
Other	32	13 (41.9%)	10 (31.3%)^d

In the group of treatment duration, compared with 3–7 days group, ^aP < 0.05
In the group of daily dose, compared with 1.5 mg/kg/days group, ^bP < 0.05
In the group of medication mode, compared with polymyxin B monotherapy group, ^cP < 0.05; compared with polymyxin + tigecycline + fosfomycin group, ^dP < 0.05

ISSN: 1471-2334